MedPath

Feasibility study of adjuvant chemotherapy with combination Docetaxel AND Daily Oral Cyclophosphamide for Japanese breast cancer patients.

Phase 2
Conditions
Breast Cancer
Registration Number
JPRN-UMIN000006673
Lead Sponsor
Shiga University of Medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1. Bilateral breast cancer in same time 2. Active double cancer 3. Inflammatory breast cancer 4. Male breast cancer 5. Severe drug allergic history 6. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infartion within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency) 7. Active infections 8. Peripheral nerve disorders 9. Massive pleural or pericardial effusion 10. Severe edema 11. Interstitial lung disease, pulmonary fibrosis 12. The case which has an underlying disease which needs combined use with steroid 13. Psychiatric disease 14. Pregnant or lactating women 15. Other conditions not suitable for this study 16. Allergy against polysorbert 80

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Feasibility
Secondary Outcome Measures
NameTimeMethod
Safety, Disease-free survival
© Copyright 2025. All Rights Reserved by MedPath